Press Releases Latest Jan 04, 2023 Open Letter to Shareholders from CEO Paul Levesque Press Releases Year None20232022202120202019201820172016201520142013 Jan 04, 2023 Open Letter to Shareholders from CEO Paul Levesque Dec 01, 2022 Theratechnologies Announces Update from Ongoing TH1902 Study Oct 26, 2022 Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Oct 13, 2022 Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update Oct 12, 2022 Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium Oct 03, 2022 Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population Sep 26, 2022 Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update Sep 19, 2022 Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference Sep 12, 2022 Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Aug 02, 2022 Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 1 - 10 of 298
Oct 26, 2022 Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
Oct 13, 2022 Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
Oct 12, 2022 Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium
Oct 03, 2022 Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population
Sep 26, 2022 Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update
Sep 12, 2022 Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth
